.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Cantor Fitzgerald
Federal Trade Commission
Chinese Patent Office
Daiichi Sankyo
AstraZeneca
Johnson and Johnson
Moodys
Harvard Business School

Generated: November 22, 2017

DrugPatentWatch Database Preview

Galen Uk Company Profile

« Back to Dashboard

What is the competitive landscape for GALEN UK , and when can generic versions of GALEN UK drugs launch?

GALEN UK has one approved drug.

There are eighteen US patents protecting GALEN UK drugs.

There are two hundred and seventeen patent family members on GALEN UK drugs in nineteen countries and six supplementary protection certificates in four countries.

Summary for Galen Uk

International Patents:217
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Galen Uk

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,070,766Delivery of physiologically active compounds through an inhalation route► Subscribe
7,045,119Delivery of diazepam through an inhalation route► Subscribe
9,211,382Drug condensation aerosols and kits► Subscribe
7,070,764Delivery of analgesics through an inhalation route► Subscribe
7,988,952Delivery of drug esters through an inhalation route► Subscribe
6,803,031 Delivery of erectile dysfunction drugs through an inhalation route► Subscribe
7,485,285Delivery of antidepressants through an inhalation route► Subscribe
6,780,400 Delivery of antiemetics through an inhalation route► Subscribe
7,070,761Delivery of nonsteroidal antiinflammatory drugs through an inhalation route► Subscribe
7,442,368Delivery of stimulants through an inhalation route► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Galen Uk Drugs

Country Document Number Estimated Expiration
Hong Kong1081888► Subscribe
World Intellectual Property Organization (WIPO)03026631► Subscribe
Japan4578773► Subscribe
World Intellectual Property Organization (WIPO)02094243► Subscribe
New Zealand529298► Subscribe
Poland364002► Subscribe
World Intellectual Property Organization (WIPO)03037307► Subscribe
Austria425746► Subscribe
World Intellectual Property Organization (WIPO)02094235► Subscribe
World Intellectual Property Organization (WIPO)02094241► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Galen Uk Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3Finland► Subscribe
2013 00046Denmark► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
2013 00046Denmark► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
90040-2Sweden► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
00609Netherlands► SubscribePRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
0609Netherlands► SubscribePRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Covington
Citi
Argus Health
Harvard Business School
AstraZeneca
McKinsey
Moodys
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot